Last updated 14 months ago

A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer

19 patients around the world
Available in Brazil
D'Or Institute for Research and Education
1Research sites
19Patients around the world
This study is for people with
Prostate cancer
Requirements for the patient
From 18 Years
Male
Medical requirements
Sites
Instituto D'Or de Pesquisa e Ensino - Sao Paulo
Recruiting
Av. República do Líbano, 611 - Ibirapuera, São Paulo - SP, 04501-000
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy